A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

Por Evens, A. M., Carson, K. R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P. M., Caimi, P. F., Gregory, S. A., Gordon, L. I.
Publicado em 2013

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

Por Evens, A. M., Carson, K. R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P. M., Caimi, P. F., Gregory, S. A., Gordon, L. I.
Publicado no Ann Oncol (2014)

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

Por Evens, A. M., Jovanovic, B. D., Su, Y.-C., Raisch, D. W., Ganger, D., Belknap, S. M., Dai, M.-S., Chiu, B.-C. C., Fintel, B., Cheng, Y., Chuang, S.-S., Lee, M.-Y., Chen, T.-Y., Lin, S.-F., Kuo, C.-Y.
Publicado em 2011

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy

Por Abramson, J. S., Feldman, T., Kroll-Desrosiers, A. R., Muffly, L. S., Winer, E., Flowers, C. R., Lansigan, F., Nabhan, C., Nastoupil, L. J., Nath, R., Goy, A., Castillo, J. J., Jagadeesh, D., Woda, B., Rosen, S. T., Smith, S. M., Evens, A. M.
Publicado no Ann Oncol (2014)

A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era

Por Hosein, P.J., Maragulia, J.C., Salzberg, M.P., Press, O.W., Habermann, T.M., Vose, J.M., Bast, M., Advani, R.H., Tibshirani, R., Evens, A.M., Islam, N., Leonard, J.P., Martin, P., Zelenetz, A.D., Lossos, I.S.
Publicado em 2014